- EVerZom, a Paris, France-based biopharmaceutical company specialized in the bioproduction of exosomes, raised €1.1m in funding
- Backers also included institutional and private investors
- This funding will also speed up the platform development and scale-up, to allow routine clinical-grade production by 2022
- Led by Jeanne Volatron, Co-founder and President, EVerZom is to develop an exosome bioproduction platform
- Exosomes are biological nanoparticles released by cells as an intercellular communication system to transport biomolecules
- They have the ability to deliver therapeutics or regenerate tissue in several pathologies, including osteoarthritis, heart failure
